We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

100 hedge funds and large institutions have $64M invested in Sanofi Contingent Value Rights in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $57.4M → $64M (+$6.63M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5% less funds holding

Funds holding: 105100 (-5)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

50% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 16

Holders
100
Holders Change
-5
Holders Change %
-4.76%
% of All Funds
2.29%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
8
Reduced
16
Closed
16
Calls
$612K
Puts
Net Calls
+$612K
Net Calls Change
+$21K

GCVRZ Hedge Fund Activity: Q1 2018 in Review

100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2018, worth a combined $64M — up 12% from $57.4M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 12 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 8 added.

The largest buyer was New Generation Advisors, adding an estimated $241K. The largest seller was B. Riley Financial, exiting entirely with an estimated $76K sold.

  • 100 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2018, down from 105 in Q4 2017.
  • Funds reported $64M of Sanofi Contingent Value Rights stock for Q1 2018, up 12% quarter-over-quarter.
  • 12 funds opened new Sanofi Contingent Value Rights positions in Q1 2018 and 16 closed out, a net change of -4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2018 was New Generation Advisors, an estimated $241K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2018 was B. Riley Financial, an estimated $76K sold.

Based on aggregated 13F filings for Q1 2018.